NCT04102553View on ClinicalTrials.gov

F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 6, 2019

Primary Completion Date

October 30, 2020

Study Completion Date

March 19, 2021

Conditions
Prostate CancerProstate Cancer Recurrent
Interventions
DRUG

F-18-PSMA-1007

Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.

DRUG

F-18-Fluorocholine

Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.

Trial Locations (6)

Unknown

Centre Jean Perrin Clermont-Ferrand, Clermont-Ferrand

Centre Léon Bérard LUMEN, Lyon

Hôpitaux de Brabois (Vandoeuvre-les-Nancy), Nancy

Hôpital Européen Georges-Pompidou, Paris

Hôpital Tenon, Paris

Hospices Civils de Lyon, Pierre-Bénite

All Listed Sponsors
lead

ABX advanced biochemical compounds GmbH

INDUSTRY

NCT04102553 - F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence | Biotech Hunter | Biotech Hunter